Flow cytometric analysis of apoptosis in Jurkat cells. Jurkat cells (Human T-cell leukemia; ATCC TIB-152) were preincubated with the following: no inhibitor (top and bottom left panels), 20 µM Z-LEHD-FMK (top and bottom center panels) or 20 µM control inhibitor, Z-FA-FMK (top and bottom right panels) for 30 min, and then either left untreated (bottom row) or treated with 4 µM of campthothecin for 3 hr (top row). Following incubation, cells were collected and stained with PE-Annexin V (Cat. No. 559763) to identify cells undergoing apoptosis. The results indicate that in campthothecin treated cells approximately 42% of the cells were induced to undergo apoptosis and the use of the caspase-9 inhibitor Z-LEHD-FMK reduced the level of apoptosis to half of that level observed in treated controls. Cells treated with Z-FA-FMK (Cat. No. 550411) showed similar results to the treated cells without inhibitor, indicating that the control inhibitor did not attenuate apoptosis.

Flow cytometric analysis of apoptosis in Jurkat cells.  Jurkat cells (Human T-cell leukemia; ATCC TIB-152) were preincubated with the following: no inhibitor (top and bottom left panels), 20 µM Z-LEHD-FMK (top and bottom center panels) or 20 µM control inhibitor, Z-FA-FMK (top and bottom right panels) for 30 min, and then either left untreated (bottom row) or treated with 4 µM of campthothecin for 3 hr (top row). Following incubation, cells were collected and stained with PE-Annexin V (Cat. No. 559763) to identify cells undergoing apoptosis. The results indicate that in campthothecin treated cells approximately 42% of the cells were induced to undergo apoptosis and the use of the caspase-9 inhibitor Z-LEHD-FMK reduced the level of apoptosis to half of that level observed in treated controls. Cells treated with Z-FA-FMK (Cat. No. 550411) showed similar results to the treated cells without inhibitor, indicating that the control inhibitor did not attenuate apoptosis.